导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.11% | 2289/4764 |
| 近一周 | -1.68% | 3104/5455 |
| 近一月 | -5.06% | 2129/5409 |
| 近一季 | -8.89% | 2845/5227 |
| 近半年 | -2.45% | 2316/4921 |
| 近一年 | 2.35% | 2077/4391 |
| 近两年 | 41.83% | 1796/2946 |
| 近三年 | 27.64% | 1162/2246 |
| 成立以来 | 175.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.27% 1746/4961 |
11.72% 2303/5312 |
- - |
- - |
| 2025 | 19.22% 2237/4813 |
-0.76% 2400/3635 |
3.27% 1073/4076 |
15.28% 2824/4524 |
0.92% 1662/4813 |
| 2024 | 13.92% 1092/3463 |
4.50% 451/2808 |
-1.04% 903/3014 |
13.46% 2164/3129 |
-2.90% 2203/3463 |
| 2023 | -6.13% 814/2656 |
5.24% 809/2280 |
-2.91% 707/2385 |
-2.53% 688/2515 |
-5.74% 1485/2655 |
| 2022 | -19.80% 901/2207 |
-11.53% 522/1919 |
6.39% 712/2016 |
-14.39% 1084/2113 |
-0.47% 1610/2208 |
| 2021 | -0.24% 746/1822 |
-0.48% 371/1255 |
6.42% 752/1330 |
-6.08% 899/1466 |
0.29% 1142/1822 |
| 2020 | 23.29% 656/1250 |
-9.47% 681/1028 |
13.84% 587/1067 |
7.59% 772/1164 |
11.19% 558/1184 |
| 2019 | 39.05% 290/1092 |
27.23% 353/754 |
0.46% 170/804 |
2.14% 319/850 |
6.52% 600/918 |
| 2018 | -16.94% 117/834 |
- - |
- - |
- - |
-11.26% 274/691 |
| 2017 | 27.08% 94/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.01% 167/605 |
- - |
- - |
- - |
- - |
| 2015 | 20.89% 113/575 |
- - |
- - |
- - |
- - |
| 2014 | 55.39% 52/237 |
- - |
- - |
- - |
- - |
| 2013 | -8.50% 137/186 |
- - |
- - |
- - |
- - |
| 2012 | 12.64% 23/140 |
- - |
- - |
- - |
- - |
| 2011 | -17.67% 18/102 |
- - |
- - |
- - |
- - |
| 2010 | -9.00% 19/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 富国沪深300指数增强A VS. 长安沪深300非周期A(740101) |